ProSci

ANG-1 Recombinant Protein

Product Code:
 
PSI-40-229
Product Group:
 
Recombinant Proteins
Supplier:
 
ProSci
Regulatory Status:
 
RUO
Target Species:
 
Human
Storage:
 
The lyophilized ANG-1 recombinant protein is stable for at least 2 years from date of receipt at -20°C. Reconstituted ANG-1 is stable for at least 3 months when stored in working aliquots with a carrier protein at -20°C. As with any protein, expos
 

No additional charges, what you see is what you pay! *

CodeSizePrice
PSI-40-229-0.005mg0.005mg£300.00
Quantity:
PSI-40-229-0.02mg0.02mg£428.00
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 14-21 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • Show All

Further Information

Additional Names:
AGP1, AGPT, ANG1, KIAA0003, Angiopoietin-1, ANG-1
Background:
Angiopoietin-1 (Ang-1) is a secreted ligand for Tie-2, a tyrosine-kinase receptor expressed primarily on vascular endothelial cells and early hematopoietic cells. Ang-1/ Tie-2 signaling promotes angiogenesis during the development, remodeling, and repair of the vascular system. Transgenic mice lacking expression of either Ang-1 or Tie-2 fail to develop a fully functional cardiovascular system and die before birth. Postnatally, the angiogenic activity of Ang-1/Tie-2 is required during normal tissue repair and remodeling of the female endometrium in the menstrual cycle. Ang-1/Tie-2 signaling appears to be regulated by Angiopoietin-2 (Ang-2), a natural antagonist for Tie-2 that exerts its effects through an internal autocrine loop mechanism. In addition to suppressing endothelial cell activation by inhibiting the expression of adhesion and inflammatory molecules, Ang-1 enhances endothelial cell survival and capillary morphogenesis, and lessens capillary permeability. As such, Ang-1 has a potential to become an effective therapeutic agent for treating various endothelium disorders, including several severe human pulmonary diseases. The efficacy of cell-based Ang-1 gene therapy for acute lung injury (ALI) has recently been studied in a rat model of ALI (1). The results of this study show that such therapy can markedly improve lung condition and suggest that Ang-1 therapy may represent a potential new strategy for the treatment and/or prevention of acute respiratory distress injury (ARDI), a significant cause of morbidity and mortality in critically ill patients. Recombinant human ANG-1, derived from HeLa cells, is a C-terminal histidine tagged glycoprotein which migrates with an apparent molecular mass of 60.0 - 70.0 kDa by SDS-PAGE under reducing conditions. Sequencing analysis shows N-terminal sequences starting with Ser-20 and with Asp-70 of the 498 amino acid precursor protein.
Biological Activity:
Determined by its ability to induce adhesion of human umbilical vein endothelial cells (HUVEC).
NCBI Gene ID #:
284
NCBI Official Name:
angiopoietin 1
NCBI Official Symbol:
ANGPT1
NCBI Organism:
Homo sapiens
Physical State:
Lyophilized
Protein Accession #:
NP_001137.2
Protein GI Number:
20532340
Purity:
Greater than 95% by SDS-PAGE gel and HPLC analyses.

Endotoxin level is less than 0.1 ng per μg (1EU/μg).
Source:
HeLa cells
Swissprot #:
Q15389

Documents